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After more than twenty years of research, the molecular events of apoptotic cell death can be succinctly stated; diﬀerent pathways,
activated by diverse signals, increase the activity of proteases called caspases that rapidly and irreversibly dismantle condemned cell
by cleaving specific substrates. In this time the ideas that apoptosis protects us from tumourigenesis and that cancer chemotherapy
works by inducing apoptosis also emerged. Currently, apoptosis research is shifting away from the intracellular events within the
dying cell to focus on the eﬀect of apoptotic cells on surrounding tissues. This is producing counterintuitive data showing that our
understanding of the role of apoptosis in tumourigenesis and cancer therapy is too simple, with some interesting and provocative
implications. Here, we will consider evidence supporting the idea that dying cells signal their presence to the surrounding tissue
and, in doing so, elicit repair and regeneration that compensates for any loss of function caused by cell death. We will discuss
evidence suggesting that cancer cell proliferation may be driven by inappropriate or corrupted tissue-repair programmes that are
initiated by signals from apoptotic cells and show how this may dramatically modify how we view the role of apoptosis in both
tumourigenesis and cancer therapy.
1. Introduction
The idea that apoptosis is a homeostatic mechanism that
can act as a counterbalance to cell proliferation is central
to our understanding of programmed cell death (reviewed
by Melino et al. [1]). Inherent in this idea is the existence
of cell-cell signalling that communicates a cell’s behaviour
and fate to those surrounding it. We now have a detailed
understanding of how a range of diﬀerent stimuli can induce
apoptosis in a cell, which includes the key molecules within
a dying cell that either transduce death signals or actively
destroy the condemned cell. The common theme that
emerges is the activation of specific intracellular proteases
(the caspases) which cleave critical substrates and thus
generate the typical morphological and biochemical changes
of apoptosis. Apoptotic stimuli first trigger the assembly of
protein complexes that are activation platforms for initiator
caspases (such as caspase-8 and -9). Activated initiators
then cleave and activate the precursors of the executioner
caspases (such as caspase-3 and -7) that subsequently act on
the various cellular substrates [2]. This valuable knowledge
provides a robust mechanistic understanding of the cell-
intrinsic mechanisms of death, but it does not explain the
cell-cell communication that couples proliferation and cell
death.
Apoptosis has traditionally been called the silent cell
death because it does not trigger an inflammatory response,
but more recent studies have uncovered evidence of
paracrine signals originating from apoptotic cells. These
studies, which are from several diﬀerent model systems,
suggest that the appearance of apoptotic cells can constitute
a signal for the proliferation of stem or progenitor cell
populations and that this compensatory proliferation is vital
for the repair and regeneration of damaged tissue. Thus,
apoptosis is far from being a silent cell death, and, even in
death, apoptotic cells seem to play a key function in tissue
homeostasis.

























Figure 1: Apoptotic stimuli activate caspases, triggering the proteolysis of a large number of intracellular substrates. The cleavage of many
of these, including iCAD and lamins, is necessary for the morphological and biochemical changes of apoptosis. Other substrates have as
yet undefined roles, while the cleavage of iPLA2 is critical for the paracrine signalling that induces compensatory proliferation. Cleavage
of iPLA2 increases its activity, so raising the levels of PGE2 and LPC. PGE2 in turn activates EP2 G protein-coupled receptors on stem or
progenitor cells. Intracellular signalling downstream of EP2 activates β-catenin and leads to cell proliferation. LPC and ATP may indirectly
induce compensatory proliferation through the recruitment of macrophages.
2. Apoptosis, Caspases, and Repair
and Regeneration
Studies in Drosophila, Xenopus, planaria, and Hydra have
revealed a role for apoptotic cells in repair and regeneration
[3–6], and the first clear evidence of its role in mammalian
repair and regeneration came from a study using caspase-
null mice [7]. Skin and liver regeneration was investigated by
studying the rate of wound healing in the skin and the rate
of liver regeneration following partial hepatectomy. Li et al.
reported that the loss of caspase-3 and/or caspase-7markedly
reduced the rate of tissue repair in both instances. Follow-
up in vitro experiments showed that apoptotic cells released
prostaglandin E2 (PGE2) in a caspase-dependent fashion and
that this induced the proliferation of various stem cell types
[7] (Figure 1).
A potential role for apoptosis in the repair and regener-
ation of pancreatic β-cells has also been uncovered [8]. In
this model, caspase activity was also required, although the
signal from apoptotic cells appeared to be membrane-bound
microparticles derived from blebbing cells, and the specific
signalling molecule or molecules involved have yet to be
identified. Nonetheless, these data show that there are likely
to be several diﬀerent types of signals driving regeneration
that originate from apoptotic cells.
3. Prostaglandins: The Role of Caspases in Their
Generation and Their Effects on Target Cells
Prostaglandins have already been established as playing a
role in tissue repair [9, 10], although their increase in con-
centration was not linked to apoptotic cells. Prostaglandins
are eicosanoids, a group of rapidly synthesized signalling
molecules that play critical roles in inflammation and other
processes. The rate-limiting step in eicosanoid generation is
the conversion of membrane phospholipids to arachidonic
acid by phospholipase A2. Prostaglandins are subsequently
formed by the action of cyclooxygenase enzymes on arachi-
donic acid and can then elicit a range of eﬀects by binding
to G protein-coupled receptors on target cells. They are
also rapidly inactivated, and so, without persistent stimulus
for their generation, their signalling is short-lived. During
apoptosis arachidonic acid is released due to the caspase-3-
dependent cleavage of Ca2+-independent phospholipase A2
(iPLA2), an event that increases the catalytic activity of iPLA2
and raises PGE2 levels [11].
4. PGE2 and Activation of β-Catenin
It is not yet clear how PGE2 induces compensatory prolifer-
ation, but there are clues that implicate β-catenin signalling.
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In both zebrafish and mice, stem cell regulation by Wnt/β-
catenin signalling has been shown to require PGE2; thus β-
catenin activation by PGE2 has been described as a master
regulator of stem cells in tissue regeneration [12].
Of the four distinct G protein-coupled receptors to which
PGE2 binds (EP1-EP4; [13]), EP2 has been shown to activate
β-catenin. In the absence of activating stimuli, β-catenin
is found in a cytoplasmic complex with the proteins axin,
adenomatous polyposis coli (APC), and glycogen synthase
kinase-3β (GSK-3β). In this complex GSK-3β phospho-
rylates β-catenin, inducing its ubiquitination and rapid
proteosomal degradation, so preventing β-catenin signalling
[14]. PGE2 binding to EP2 leads to dissociation of the G
protein subunits Gαs and βγ. While Gαs binds to axin, leading
to the release of GSK-3β, the βγ subunits activate AKT which
inactivates GSK-3β by phosphorylation [15].
To this point the focus has been on the role of apoptosis
in normal tissue repair and regeneration; however, there are
many obvious links to tumourigenesis. For example, partial
hepatectomy promotes tumour formation, APC is a tumour
suppressor, and PGE2 is known to contribute to tumour
promotion. In vitro PGE2 increases cellular proliferation and
induces other cell behaviour typical of cancer cells such as
reduced expression of E-cadherin, reduced apoptosis, and
anchorage-independent growth [16]. In addition, EP2-null
mice form fewer lung and skin tumours than wild-type mice
when exposed to chemical carcinogens [17, 18]. Similarly,
mice lacking microsomal prostaglandin E synthase-1 show
reduced colon tumour formation [19]. Since spontaneous
apoptosis of tumour cells is frequently occurring within
tumours [20], it is possible that these phenotypes are, at
least in part, due to an impaired compensatory proliferation
of tumor cells. Therefore, these observations prompt the
following question: what is the role of apoptosis-induced
compensatory proliferation in cancer development and
cancer treatment?
5. Puma, Apoptosis, and Tumourigenesis
The idea that perturbing the balance between death and
proliferation causes disease emerged very early within the
apoptosis research field [21]. Perhaps the best example is
cancer; the observation that cancers often acquire mutations
that prevent apoptosis has been explained by the survival
of precancerous cells (that would otherwise die) giving rise
to neoplasia. However, new data, building on the ideas
of apoptosis-induced compensatory proliferation in normal
repair and regeneration, show that the role of apoptosis in
tumourigenesis does not end with the death of cell.
The first pieces of evidence come from two studies of
lymphoma formation performed in PUMA-null mice [22,
23]. In both studies lymphomagenesis was induced by γ-
irradiation. Both groups also showed that γ-irradiation-
induced apoptosis was markedly reduced in PUMA-null ani-
mals. This is rather unsurprising as PUMA is a proapoptotic
(BH3-only) member of the Bcl-2 family and a key player
in the mitochondrial apoptotic pathway activated by DNA
damage [24]. PUMA acts by either inhibiting Bcl-2 function
or by activating Bax and Bak, so triggering the release of
cytochrome c from mitochondria. The subsequent Apaf-1-
dependent caspase activation induces apoptosis [25].
What is surprising is that, following γ-irradiation,
PUMA-null mice showed decreased tumour incidence. Inter-
estingly, irradiation of wild-type mice resulted in com-
pensatory proliferation of a population of hematopoietic
stem/progenitor cells, but this proliferation was decreased
in PUMA-null animals. The idea that PUMA-dependent
apoptotic cell death was driving the compensatory prolifer-
ation is driven home by one further experiment: Michalak
et al. induced leukocyte apoptosis in PUMA-null animals
with a glucocorticoid (which causes PUMA-independent
apoptosis) and by this means restored γ-irradiation-induced
lymphomagenesis in these animals [22].
Another key piece of evidence comes from a mouse
model of chemical carcinogenesis. Diethylnitrosamine
(DEN) is an DNA-alkylating agent that induces apoptosis
and is also a known hepatocarcinogen. Qiu et al. [26] showed
that DEN treatment of wild-type mice induced hepatocyte
apoptosis which was reduced in PUMA-deficient mice.
Just as was seen in γ-irradiation-induced lymphoma-
genesis, PUMA-null mice showed both decreased tumour
incidence and also decreased tumour size. Qiu et al. also
observed that DEN induced a PUMA-dependent compen-
satory proliferation in the liver. The authors concluded that
the DEN-induced apoptosis causes increased, or compen-
satory, proliferation that drives hepatocarcinogenesis, an idea
consistent with the observations that apoptotic hepatocytes
are often surrounded by proliferating cells following DEN-
treatment [27]. Indeed, the role of compensatory prolif-
eration in DEN-induced hepatocellular carcinoma is well
supported by other studies, although these studies implicate
a major role for inflammation rather than apoptosis in
compensatory proliferation [27, 28]. Interestingly, all these
studies are foreshadowed by observations linking carbon
tetrachloride-induced hepatotoxicity and compensatory pro-
liferation to carcinogenesis, although again, the causal role of
apoptotic cells was not investigated [29].
The signalling events involved in inducing compensatory
proliferation in lymphomagenesis and hepatocarcinogenesis
remain unexplored, so there is as yet no direct link to
PGE2, the key signalling molecule identified by Li et al. [7].
Nonetheless, all the data are consistent with amodel in which
carcinogen-induced DNA damage kills some cells by apopto-
sis and that these apoptotic cells generate a proproliferation
signal. This signal then promotes tumourigenesis by acting
on surrounding cells that have acquired oncogenic mutations
as a result of sublethal levels of DNA damage.
6. Radiotherapy, Apoptosis, and
Tumour Repopulation
A similarly provocative idea has been put forward by the
same group that originally described the role of mammalian
caspases in regeneration [30]. Following radiotherapy to kill
cancer cells, there is a rapid proliferation of the surviving
cancer cells that repopulate the tumour. Huang et al. [30]















Figure 2: Radio- or chemotherapy induces cancer cell apoptosis generating proliferation signals that drive the rapid proliferation of surviving
cancer cells which repopulate the tumour by generating signals that act directly on stem/progenitor cells or by recruiting macrophages (a).
The role of PUMA in compensatory proliferation has led to the suggestion that blocking caspase-mediated cleavage of iPLA2 with small
molecule caspase inhibitors may improve patient outcomes by preventing this compensatory proliferation. However the general applicability
of this model is uncertain for several reasons. Firstly, inDrosophila development blocking apoptosis in some circumstances produces undead
cells whose persistent signalling increases compensatory proliferation (b). Secondly, while caspase inhibitors block apoptosis, the irradiated
or drug-treated cells may still die by nonapoptotic processes or become senescent, which may induce compensatory proliferation as well (c).
investigated the mechanism of this repopulation using a
mouse model and found that it was caspase-3-dependent
and, like tissue regeneration, involved PGE2. Interestingly,
the overexpression of caspase-3 in MCF-7 cells (which
lack caspase-3) increased tumour growth in a xenograft
model, indicating that, even in the absence of therapy,
caspase-3 plays an unexpected protumourigenic role. The
mechanism underlying the increased rate of tumour growth
seen with unirradiated MCF-7 cells overexpressing caspase-3
was not investigated. Huang et al. speculated that the caspase
activation accompanying spontaneous apoptotic cell death
may be the cause of this increased rate in tumour growth.
In the same study the role of stromal cells in caspase-
3-dependent tumour repopulation was assessed using a
syngenic tumour cell line transplanted into wild-type and
caspase-3-null mice. Cells transplanted into wild-type mice
formed larger tumours compared to the cells transplanted
into null animals, suggesting that the tumour cell-stromal
interactions supporting tumour growth are also caspase-3
dependent.
Lastly, Huang et al. [30] investigated the relationship
between levels of activated caspase-3 in clinical tumour
samples and patient outcome. This analysis revealed a
positive correlation between expression of active caspase-
3 in tumours and poorer prognosis in patients with head
and neck carcinoma and advanced breast cancer, adding
weight to the counterintuitive idea that increased apoptosis
contributes to disease progression.
Again, the idea of compensatory proliferation induced
by apoptotic cells was evoked to explain these observations.
In such a model, radiotherapy and chemotherapy induces
apoptosis by activating caspases, either through the “intrin-
sic” or mitochondrial pathway [31] or by RIP-kinase-
dependent activation of caspase-8 [32]. While this apoptosis
does indeed kill the cancer cells, the unintended consequence
is the inevitable increase in proproliferation signalling from
the dying cells. Unfortunately, the result is not normal tissue
regeneration, but the rapid proliferation of surviving cancer
cells that repopulate the tumour (Figure 2(a)). Thus, the
very mechanism of cell death induced by most currently
employed cancer chemotherapy can limit the eﬃcacy of that
therapy.
This provocative idea led Huang et al. to the counter-
intuitive suggestion that treatment of patients with radio-
or chemotherapy supplemented by caspase inhibitors may
improve patient outcomes by blocking caspase-mediated
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cleavage of iPLA2 and so prevent compensatory proliferation.
While the toxicity of the caspase inhibitor zVAD-fmk
precludes its in vivo use [33], inhibitors such as Q-VD-OPh
are available and suitable for this purpose [34]. These caspase
inhibitors will, of course, also block cancer cell apoptosis, but
there is reason to think that the combination therapy would
still improve anticancer activity.
7. Caspase Activity Determines theMode
of Cell Death, but Blocking Activity
Does Not Necessarily Keep Cells Alive
Caspase activity induces apoptosis but blocking caspase
activity does not necessarily rescue cells from cell death.
While caspase inhibitors prevent the appearance of the mor-
phological and biochemical features of apoptosis induced
by anticancer agents, aﬀected cells still die by necrotic or
necroptotic processes. Thus caspase activity can determine
the mode of cell death but not necessarily the choice between
death and survival [35].
Anticancer therapy can also induce necrotic cell death
directly [36] or induce senescence [37]. Necrotic cell death
can promote tumourigenesis through induction of inflam-
mation [38], and senescence is known to generate paracrine
signals that can promote tumourigenesis such as IL-6 and
-8 [39, 40] (Figures 2(b) and 2(c)). However, the data of
Huang et al. [30] from caspase-null animals suggest that
signals derived from apoptotic cells following radiotherapy
are the most important. This is either because apoptosis
was the predominant cell fate induced by radiotherapy or
because paracrine signals from apoptotic cells are more
potent tumour promoters. Whether this is true of other
cancer therapies still needs to be tested through further
investigation of apoptotic and nonapoptotic cell death and
of the generation of tumour-promoting paracrine signalling
molecules in tumours. Testing the generality of these con-
clusions is particularly important as studies of compensatory
proliferation in Drosophila development show that blocking
apoptosis in some contexts can result in “undead” cells
whose persistent signaling increases, rather than decreases,
proliferation [41–45]. Whatever the outcome of such studies,
a consideration of cell death-derived signalling appears to be
necessary when weighing the factors that limit the eﬃcacy of
chemotherapy.
Targeting caspase activity may be attractive as these
proteases drive the apoptotic process and so the production
of signals that induce compensatory proliferation. However,
interfering with the signals themselves may also work, and
this is an attractive alternative as there are already a range of
nonsteroidal anti-inflammatory drugs (NSAIDs) that aﬀect
prostaglandin production. Indeed, NSAIDs have been, and
continue to be, tested for anticancer therapy although not
for the reasons discussed here (there are several diﬀerent
rationales for testing the anticancer activity of NSAIDs
from their antiangiogenic activity to their ability to reduce
chemotherapy-induced neuropathy [46, 47]). The limitation
of this approach is that other potent regeneration/repair sig-
nals emanating from apoptotic cells, such as microparticles,
may not be sensitive to NSAIDs, and targeting the apoptotic
process itself might therefore be more eﬃcacious.
8. A Conspiracy between Apoptotic
Cells and Immune Cells May Promote
Tumor Development
So far we have discussed how apoptotic cells talk to stem
or progenitor cell populations and so induce tissue repair.
However, there is good evidence that other cell types are lis-
tening to apoptotic cells, notably phagocytes. Thus, apoptotic
cells initiate their own clearance by actively releasing several
soluble factors that attract phagocytic cells. These so-called
find-me signals include the nucleotides ATP and UTP [48,
49], lysophosphatidylcholine (LPC) [50], and sphingosine-
1-phosphate (S1P) [51](reviewed in [52]). Interestingly, the
release of two of these factors has been shown to depend
on caspase activity within apoptotic cells. Release of ATP
occurs via the membrane channel protein Pannexin-1, which
becomes activated by caspase-3/7-mediated cleavage [49]. In
addition caspase-mediated activation of iPLA2 is not only
involved in raising PGE2 levels (as discussed above) but
at the same time leads to LPC production by hydrolysis
of membrane phosphatidylcholine [50]. ATP and LPC are
linked primarily with attracting professional phagocytes such
as macrophages to facilitate clearance of apoptotic bodies.
However, these macrophages also represent a likely source
of wound healing signals [50], such as platelet-derived
growth factors and TGF-β1, that stimulate proliferation of
surrounding epithelial cells and fibroblasts and may also
act on tumor cells themselves [53, 54]. In fact, there is
accumulating evidence from a number of tumor models
to suggest that these macrophages contribute to tumor cell
proliferation and metastasis [55, 56] and thus enhance the
progression of tumors towards malignancy. So, apoptotic
cells appear to promote tissue regeneration and repair
processes by at least two mechanisms: one is a mechanism
involving the generation of signals that act directly on
stem and/or progenitor cells, and the other is an indirect
mechanism that involves recruitment of macrophages which
subsequently release proproliferative factors.
9. HowDo These New Ideas Fit with the
Predominant View of Apoptosis in Cancer?
The activation of many oncogenes can induce apoptosis,
and the loss of tumour suppressors can prevent apoptosis,
and this leads to the predominant view that apoptosis
protects us from cancer by removing precancerous cells and
that cancer can only occur when the apoptotic process is
compromised [48]. Similarly, there is much evidence to
show that radiotherapy and chemotherapeutic drugs induce
apoptosis [31], although this is not the only fate that can be
induced.
At first glance, the new idea that apoptosis promotes
tumourigenesis and limits the eﬃcacy of therapy challenges
the predominant viewpoint, but the apparently conflicting
roles of apoptosis are not at all incompatible. Firstly,
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a maelstrom of often conflicting changes occurs during
tumourigenesis but the emergence of a tumour represents
selection of cells which have struck a balance between
these changes, that is compatible with cell proliferation.
Depending on the sequence of events that lead to a tumour
being formed, it is possible that at early stages apoptotic
cell death is a promoting event but that the acquisition of
mutations that compromise apoptosis at a later stage drives
disease progression. Indeed, apoptosis or inflammation may
increase PGE2 levels at early stages of the disease, but
autocrine PGE2 production can occur at a later stage of the
disease [49]. Similarly, eﬀective cancer treatment is defined
by the extent of tumour regression, and identification of
an eﬀective therapy suggests that balance between apoptotic
cell death and proproliferation signals from apoptotic cells
favours net cell loss. The new findings suggest that interfering
with apoptosis may push this balance even further towards
cell loss by blocking compensatory proliferation and so
enhance the eﬃcacy of therapy.
10. Final Thoughts
The studies outlined here show that apoptotic cells, far from
being silent, signal their presence to stem and progenitor
cells in surrounding tissue and in doing so elicit repair and
regeneration. This coupling of cell loss with a compensatory
proliferation and diﬀerentiation is consistent with current
models of the role of apoptosis in tissue homeostasis.
The obvious corollary is that the activation of corrupted
proliferation and tissue repair programmes in stem cells can
contribute to tumourigenesis, and this is also being borne out
by experimental data.
Intriguing and important as the new findings are, we
should end with some words of caution. The general
relevance of the new roles of apoptosis in tumourigenesis and
therapy has not been tested. Given the diversity of cancers,
it seems likely that the development of some tumours may
involve much apoptosis-driven tumour promotion, while in
others it may be of little importance.
Similarly, it has been assumed that compensatory pro-
liferation induced by radiotherapy will also be induced by
cytotoxic therapy that triggers apoptosis and that the new
findings are therefore relevant to other cancer therapies
[30]. This has yet to be established, and even if it is,
considering the wide range of diﬀerent chemistries, diﬀerent
mechanisms of action and diﬀerent pharmacokinetics and
pharmacodynamics associated with chemotherapy, some
drugs may be better or poorer inducers of compensatory
proliferation.
One obvious diﬀerence between radiotherapy and chem-
otherapy is that radiotherapy is typically delivered for a
very short period of time compared to chemotherapy. Thus,
after radiotherapy, compensatory proliferation occurs in the
absence of a continuing apoptotic stimulus. In contrast,
a chemotherapeutic drug may persist at pharmacologi-
cally relevant concentrations over the period of time that
encompasses compensatory proliferation. In this instance,
a cytotoxic drug may kill the activated stem cells as they
proliferate, leading to a second round of cell death. These
deaths in turn may activate a further round of compensatory
proliferation and so on, until the drug’s concentration falls
to subtoxic levels. The outcome in this situation is hard to
predict but will be aﬀected by the sensitivity of the stem cells
to the drug, the proportion of cells that are able to respond
to the paracrine signals and the pharmacokinetics of the
particular drug.
Finally, there are also indications that PGE2 is not
the only method of “beyond-the-grave” communication
undertaken by apoptotic cells [8], nor is β-catenin signalling
the only pathway implicated in compensatory proliferation
[3, 26]. Finding out just how noisy the supposedly “silent
cell death” really is will help in understanding how signals
from apoptotic cells might regulate normal and pathological
processes and build a more complete picture of the apoptotic
process.
Acknowledgments
The authors would like to thank Dr. J. McMahon for careful
reading of the paper and constructive comments and to
the anonymous reviewers for their thoughtful and helpful
comments. We also apologize to all those whose relevant
work we have not referenced due to space constraints.
References
[1] G. Melino, R. A. Knight, and J. C. Ameisen, “The Siren’s song:
this death that makes life live,” in Cell Death, G. Melino and D.
Vaux, Eds., John Wiley & Sons, 2010.
[2] R. C. Taylor, S. P. Cullen, and S. J. Martin, “Apoptosis: con-
trolled demolition at the cellular level,” Nature Reviews
Molecular Cell Biology, vol. 9, no. 3, pp. 231–241, 2008.
[3] Y. Fan and A. Bergmann, “Distinct mechanisms of apoptosis-
induced compensatory proliferation in proliferating and dif-
ferentiating tissues in the Drosophila eye,” Developmental Cell,
vol. 14, no. 3, pp. 399–410, 2008.
[4] A. S. Tseng, D. S. Adams, D. Qiu, P. Koustubhan, andM. Levin,
“Apoptosis is required during early stages of tail regeneration
in Xenopus laevis,” Developmental Biology, vol. 301, no. 1, pp.
62–69, 2007.
[5] J. S. Hwang, C. Kobayashi, K. Agata, K. Ikeo, and T. Gojobori,
“Detection of apoptosis during planarian regeneration by
the expression of apoptosis-related genes and TUNEL assay,”
Gene, vol. 333, pp. 15–25, 2004.
[6] S. Chera, L. Ghila, K. Dobretz et al., “Apoptotic cells provide
an unexpected source of Wnt3 signaling to drive hydra head
regeneration,” Developmental Cell, vol. 17, no. 2, pp. 279–289,
2009.
[7] F. Li, Q. Huang, J. Chen et al., “Apoptotic cells activate the
“phoenix rising” pathway to promote wound healing and
tissue regeneration,” Science Signaling, vol. 3, no. 110, p. ra13,
2010.
[8] C. Bonner, S. Bacon, C. G. Concannon et al., “INS-1 cells
undergoing caspase-dependent apoptosis enhance the re-
generative capacity of neighboring cells,” Diabetes, vol. 59, no.
11, pp. 2799–2808, 2010.
[9] I. Kuhrer, R. Kuzmits, W. Linkesch, and H. Ludwig, “Topical
PGE2 enhances healing of chemotherapy-associated mucosal
lesions,” The Lancet, vol. 1, no. 8481, p. 623, 1986.
Biochemistry Research International 7
[10] V. M. Paralkar, F. Borovecki, H. Z. Ke et al., “An EP2 receptor-
selective prostaglandin E2 agonist induces bone healing,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 100, no. 11, pp. 6736–6740, 2003.
[11] G. I. Atsumi, M. Tajima, A. Hadano, Y. Nakatani, M.
Murakami, and I. Kudot, “Fas-induced arachidonic acid
release is mediated by Ca2+-independent phospholipase A2 but
not cytosolic phospholipase A2, which undergoes proteolytic
inactivation,” Journal of Biological Chemistry, vol. 273, no. 22,
pp. 13870–13877, 1998.
[12] W. Goessling, T. E. North, S. Loewer et al., “Genetic interaction
of PGE2 and Wnt signaling regulates developmental specifica-
tion of stem cells and regeneration,” Cell, vol. 136, no. 6, pp.
1136–1147, 2009.
[13] J. Reader, D. Holt, and A. Fulton, “Prostaglandin E2 EP
receptors as therapeutic targets in breast cancer,” Cancer and
Metastasis Reviews, vol. 30, no. 3-4, pp. 449–463, 2011.
[14] R. T. Moon, A. D. Kohn, G. V. De Ferrari, and A. Kaykas,
“WNT and β-catenin signalling: diseases and therapies,”
Nature Reviews Genetics, vol. 5, no. 9, pp. 691–701, 2004.
[15] M. D. Castellone, H. Teramoto, B. O. Williams, K. M. Druey,
and J. S. Gutkind, “Medicine: prostaglandin E2 promotes
colon cancer cell growth through a Gs-axin-β-catenin signal-
ing axis,” Science, vol. 310, no. 5753, pp. 1504–1510, 2005.
[16] J. E. Rundhaug and S. M. Fischer, “Molecular mechanisms of
mouse skin tumor promotion,” Cancers, vol. 2, no. 2, pp. 436–
482, 2010.
[17] Y. M. Sung, G. He, and S. M. Fischer, “Lack of expression of
the EP2 but not EP3 receptor for prostaglandin E2 results in
suppression of skin tumor development,” Cancer Research, vol.
65, no. 20, pp. 9304–9311, 2005.
[18] R. L. Keith, M. W. Geraci, S. P. Nana et al., “Prostaglandin
E2 receptor subtype 2 (EP2) null mice are protected against
murine lung tumorigenesis,” Anticancer Research, vol. 26, no.
4 B, pp. 2857–2861, 2006.
[19] Y. Sasaki, D. Kamei, Y. Ishikawa et al., “Microsomal
prostaglandin E synthase-1 is involved in multiple steps of
colon carcinogenesis,” Oncogene, vol. 31, no. 24, pp. 2943–
2952, 2012.
[20] J. F. Kerr, A. H. Wyllie, and A. R. Currie, “Apoptosis: a basic
biological phenomenon with wide-ranging implications in
tissue kinetics,” British Journal of Cancer, vol. 26, no. 4, pp.
239–257, 1972.
[21] A. H. Wyllie, “Apoptosis: cell death in tissue regulation,”
Journal of Pathology, vol. 153, no. 4, pp. 313–316, 1987.
[22] E. M. Michalak, C. J. Vandenberg, A. R. D. Delbridge et al.,
“Apoptosis-promoted tumorigenesis: γ-irradiation-induced
thymic lymphomagenesis requires Puma-driven leukocyte
death,”Genes and Development, vol. 24, no. 15, pp. 1608–1613,
2010.
[23] V. Labi, M. Erlacher, G. Krumschnabel et al., “Apoptosis
of leukocytes triggered by acute DNA damage promotes
lymphoma formation,” Genes and Development, vol. 24, no.
15, pp. 1602–1607, 2010.
[24] K. Nakano and K. H. Vousden, “PUMA, a novel proapoptotic
gene, is induced by p53,” Molecular Cell, vol. 7, no. 3, pp. 683–
694, 2001.
[25] K. Cain, S. B. Bratton, and G. M. Cohen, “The Apaf-1
apoptosome: a large caspase-activating complex,” Biochimie,
vol. 84, no. 2-3, pp. 203–214, 2002.
[26] W. Qiu, X. Wang, B. Leibowitz, W. Yang, L. Zhang, and J. Yu,
“PUMA-mediated apoptosis drives chemical hepatocarcino-
genesis in mice,” Hepatology, vol. 54, no. 4, pp. 1249–1258,
2011.
[27] S. Maeda, H. Kamata, J. L. Luo, H. Leﬀert, and M. Karin,
“IKKβ couples hepatocyte death to cytokine-driven compen-
satory proliferation that promotes chemical hepatocarcino-
genesis,” Cell, vol. 121, no. 7, pp. 977–990, 2005.
[28] T. Sakurai, G. He, A. Matsuzawa et al., “Hepatocyte necro-
sis induced by oxidative stress and IL-1α release mediate
carcinogen-induced compensatory proliferation and liver
tumorigenesis,” Cancer Cell, vol. 14, no. 2, pp. 156–165, 2008.
[29] G. M. Ledda-Columbano, O. Coni, M. Curto et al., “Mitogen-
induced liver hyperplasia does not substitute for compen-
satory regeneration during promotion of chemical hepatocar-
cinogenesis,” Carcinogenesis, vol. 13, no. 3, pp. 379–383, 1992.
[30] Q. Huang, F. Li, X. Liu et al., “Caspase 3-mediated stimulation
of tumor cell repopulation during cancer radiotherapy,”
Nature Medicine, vol. 17, no. 7, pp. 860–866, 2011.
[31] R. W. Johnstone, A. A. Ruefli, and S. W. Lowe, “Apoptosis:
a link between cancer genetics and chemotherapy,” Cell, vol.
108, no. 2, pp. 153–164, 2002.
[32] T. Tenev, K. Bianchi, M. Darding et al., “The ripoptosome,
a signaling platform that assembles in response to genotoxic
stress and loss of IAPs,” Molecular Cell, vol. 43, no. 3, pp. 432–
448, 2011.
[33] C. J. F. Van Noorden, “Editorial: the history of Z-VAD-FMK, a
tool for understanding the significance of caspase inhibition,”
Acta Histochemica, vol. 103, no. 3, pp. 241–251, 2001.
[34] D. Chauvier, S. Renolleau, S. Holifanjaniaina et al., “Targeting
neonatal ischemic brain injury with a pentapeptide-based
irreversible caspase inhibitor,” Cell Death and Disease, vol. 2,
no. 9, p. e203, 2011.
[35] P. Vandenabeele, T. Vanden Berghe, and N. Festjens, “Caspase
inhibitors promote alternative cell death pathways,” Science’s
STKE, vol. 2006, no. 358, p. pe44, 2006.
[36] D. Ditsworth, W. X. Zong, and C. B. Thompson, “Activation
of poly(ADP)-ribose polymerase (PARP-1) induces release of
the pro-inflammatory mediator HMGB1 from the nucleus,”
Journal of Biological Chemistry, vol. 282, no. 24, pp. 17845–
17854, 2007.
[37] J. Campisi and F. D’Adda Di Fagagna, “Cellular senescence:
when bad things happen to good cells,” Nature Reviews
Molecular Cell Biology, vol. 8, no. 9, pp. 729–740, 2007.
[38] A. G. Dalgleish and K. O’Byrne, “Inflammation and cancer:
the role of the immune response and angiogenesis,” Cancer
Treatment and Research, vol. 130, pp. 1–38, 2006.
[39] T. Kuilman, C. Michaloglou, L. C. W. Vredeveld et al.,
“Oncogene-induced senescence relayed by an interleukin-
dependent inflammatory network,” Cell, vol. 133, no. 6, pp.
1019–1031, 2008.
[40] V. G. Gorgoulis and T. D. Halazonetis, “Oncogene-induced
senescence: the bright and dark side of the response,” Current
Opinion in Cell Biology, vol. 22, no. 6, pp. 816–827, 2010.
[41] H. D. Ryoo, T. Gorenc, and H. Steller, “Apoptotic cells can
induce compensatory cell proliferation through the JNK and
the wingless signaling pathways,” Developmental Cell, vol. 7,
no. 4, pp. 491–501, 2004.
[42] J. R. Huh, M. Guo, and B. A. Hay, “Compensatory prolifera-
tion induced by cell death in the Drosophila wing disc requires
activity of the apical cell death caspase dronc in a nonapoptotic
role,” Current Biology, vol. 14, no. 14, pp. 1262–1266, 2004.
[43] B. S. Wells, E. Yoshida, and L. A. Johnston, “Compensatory
proliferation in Drosophila imaginal discs requires dronc-
dependent p53 activity,” Current Biology, vol. 16, no. 16, pp.
1606–1615, 2006.
8 Biochemistry Research International
[44] S. Kondo, N. Senoo-Matsuda, Y. Hiromi, and M. Miura,
“DRONC coordinates cell death and compensatory prolifera-
tion,”Molecular and Cellular Biology, vol. 26, no. 19, pp. 7258–
7268, 2006.
[45] A. Pe´rez-Garijo, F. A. Martı´n, and G. Morata, “Caspase in-
hibition during apoptosis causes abnormal signalling and de-
velopmental aberrations in Drosophila,” Development, vol.
131, no. 22, pp. 5591–5598, 2004.
[46] C. M. Ulrich, J. Bigler, and J. D. Potter, “Non-steroidal anti-
inflammatory drugs for cancer prevention: promise, perils and
pharmacogenetics,” Nature Reviews Cancer, vol. 6, no. 2, pp.
130–140, 2006.
[47] A. Albini and M. B. Sporn, “The tumour microenvironment
as a target for chemoprevention,” Nature Reviews Cancer, vol.
7, no. 2, pp. 139–147, 2007.
[48] M. R. Elliott, F. B. Chekeni, P. C. Trampont et al., “Nucleotides
released by apoptotic cells act as a find-me signal to promote
phagocytic clearance,”Nature, vol. 461, no. 7261, pp. 282–286,
2009.
[49] F. B. Chekeni, M. R. Elliott, J. K. Sandilos et al., “Pannexin
1 channels mediate ’find-me’ signal release and membrane
permeability during apoptosis,”Nature, vol. 467, no. 7317, pp.
863–867, 2010.
[50] K. Lauber, E. Bohn, S. M. Kro¨ber et al., “Apoptotic cells induce
migration of phagocytes via caspase-3-mediated release of a
lipid attraction signal,” Cell, vol. 113, no. 6, pp. 717–730, 2003.
[51] D. R. Gude, S. E. Alvarez, S.W. Paugh et al., “Apoptosis induces
expression of sphingosine kinase 1 to release sphingosine-1-
phosphate as a “come-and-get-me” signal,” FASEB Journal,
vol. 22, no. 8, pp. 2629–2638, 2008.
[52] K. Ravichandran, “Beginnings of a good apoptotic meal: the
find-me and eat-me signaling pathways,” Immunity, vol. 35,
no. 4, pp. 445–455, 2011.
[53] A. B. Roberts and L. M. Wakefield, “The two faces of
transforming growth factor β in carcinogenesis,” Proceedings
of the National Academy of Sciences of the United States of
America, vol. 100, no. 15, pp. 8621–8623, 2003.
[54] L. Barron and T. A. Wynn, “Fibrosis is regulated by Th2
and Th17 responses and by dynamic interactions between
fibroblasts and macrophages,” American Journal of Physiology,
vol. 300, no. 5, pp. G723–G728, 2011.
[55] C. Steidl, T. Lee, S. P. Shah et al., “Tumor-associated ma-
crophages and survival in classic Hodgkin’s lymphoma,” New
England Journal of Medicine, vol. 362, no. 10, pp. 875–885,
2010.
[56] B. Z. Qian, J. Li, H. Zhang et al., “CCL2 recruits inflammatory
monocytes to facilitate breast-tumour metastasis,”Nature, vol.
475, no. 7355, pp. 222–225, 2011.










Hindawi Publishing Corporation 
http://www.hindawi.com













Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Bioinformatics
Advances in
Marine Biology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Signal Transduction
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Evolutionary Biology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Biochemistry 
Research International
Archaea
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Genetics 
Research International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Advances in
Virolog y
Hindawi Publishing Corporation
http://www.hindawi.com
Nucleic Acids
Journal of
Volume 2014
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Enzyme 
Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
International Journal of
Microbiology
